Bupivacaine (AH-250; HSDB 7790; SKY 0402) is a BK/SK, Kv1, Kv3, TASK-2 K Channel and voltage-gated Na channel blocker used as an anesthetic.

NBQX (also known as FG9202) is a novel and potent antagonist of aminomethylphosphonic acid receptor (AMPAR) with IC50 of 0.7 ± 0.1 μM.

Kynurenic acid sodium is an endogenous tryptophan metabolite with activity against NMDA, glutamate, α7 nicotinic acetylcholine receptors.

CX546 is an AMPA receptor potentiator. It binds specifically to the agonist bound non-desensitized receptor, and most likely destabilizing the desensitized receptor conformation.

L-701324 (L701324), a novel, potent and selective NMDA/glycine receptor antagonist, is an orally bioactive and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor. L-701324 exhibits a beneficial action in the animal model of parkinsonian rigidity. Pre-treatment with L-701,324 improves pharmacosensitivity in a mouse kindling model.

Ibotenic Acid [(RS)-Ibotenic acid; DL-Ibotenic acid] is a highly potent excitatory amino acid agonist with activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Qm) receptor sites.

CNQX Disodium (FG-9065), the disodium salt form of CNQX, is a potent AMPA/kainate antagonist with higher water-solubility than the free acid form CNQX (Cat. No. V33762).

SYM2206 is a potent, specific and non-competitive antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor) receptors with IC50 value of 2.8 μM.

Traxoprodil (CP-101606, CP 98113, and CP101,606) is a novel, potent and selective NMDA (NR2B N-Methyl-D-Aspartate) antagonist with neuroprotective effects.

NBQX (also known as FG9202) is a novel, potent selective and competitive antagonist of aminomethylphosphonic acid receptor (AMPAR) with IC50 of 0.7 ± 0.1 μM.